Patents by Inventor Brian Safer
Brian Safer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20140348794Abstract: The present invention provides an adeno-associated virus 4 (AAV4) virus and vectors and particles derived therefrom. In addition, the present invention provides methods of delivering a nucleic acid to a cell using the AAV4 vectors and particles.Type: ApplicationFiled: August 14, 2014Publication date: November 27, 2014Inventors: John A. Chiorini, Robert M. Kotin, Brian Safer
-
Patent number: 8846389Abstract: The present invention provides an adeno-associated virus 4 (AAV4) virus and vectors and particles derived therefrom. In addition, the present invention provides methods of delivering a nucleic acid to a cell using the AAV4 vectors and particles.Type: GrantFiled: July 2, 2013Date of Patent: September 30, 2014Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: John A. Chiorini, Robert M. Kotin, Brian Safer
-
Publication number: 20130337543Abstract: The present invention provides an adeno-associated virus 4 (AAV4) virus and vectors and particles derived therefrom. In addition, the present invention provides methods of delivering a nucleic acid to a cell using the AAV4 vectors and particles.Type: ApplicationFiled: July 2, 2013Publication date: December 19, 2013Applicant: The USA, as represented by the Secretary, Department of Health and Human ServicesInventors: John A. Chiorini, Robert M. Kotin, Brian Safer, Nancy Safer
-
Patent number: 8409166Abstract: Methods and devices are disclosed for selective delivery of therapeutic substances to specific histologic or microanatomic areas of organs. Introduction of the therapeutic substance into a hollow organ space (such as an hepatobiliary duct or the gallbladder lumen) at a controlled pressure, volume or rate allows the substance to reach a predetermined cellular layer (such as the ephithelium or sub-epithelial space). The volume or flow rate of the substance can be controlled so that the intralumenal pressure reaches a predetermined threshold level beyond which subsequent subepithelial delivery of the substance occurs. Alternatively, a lower pressure is selected that does not exceed the threshold level, so that delivery occurs substantially only to the epithelial layer. Such site specific delivery of therapeutic agents permits localized delivery of substances (for example to the interstitial tissue of an organ) in concentrations that may otherwise produce systemic toxicity.Type: GrantFiled: April 26, 2011Date of Patent: April 2, 2013Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Stephen M. Wiener, Robert F. Hoyt, Jr., John R. Deleonardis, Randall R. Clevenger, Robert J. Lutz, Douglas V. Christini, Brian Safer
-
Publication number: 20100227407Abstract: The present invention provides an adeno-associated virus 4 (AAV4) virus and vectors and particles derived therefrom. In addition, the present invention provides methods of delivering a nucleic acid to a cell using the AAV4 vectors and particles.Type: ApplicationFiled: March 8, 2010Publication date: September 9, 2010Applicant: US Department of Health and Human Services, National Institutes of HealthInventors: John A. Chiorini, Robert M. Kotin, Brian Safer, Nancy Safer
-
Patent number: 7718424Abstract: The present invention provides an adeno-associated virus 4 (AAV4) virus and vectors and particles derived therefrom. In addition, the present invention provides methods of delivering a nucleic acid to a cell using the AAV4 vectors and particles.Type: GrantFiled: November 20, 2003Date of Patent: May 18, 2010Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: John A. Chiorini, Robert M. Kotin, Brian Safer
-
Publication number: 20080269718Abstract: Methods and devices are disclosed for selective delivery of therapeutic substances to specific histologic or microanatomic areas of organs. Introduction of the therapeutic substance into a hollow organ space (such as an hepatobiliary duct or the gallbladder lumen) at a controlled pressure, volume or rate allows the substance to reach a predetermined cellular layer (such as the ephithelium or sub-epithelial space). The volume or flow rate of the substance can be controlled so that the intralumenal pressure reaches a predetermined threshold level beyond which subsequent subepithelial delivery of the substance occurs. Alternatively, a lower pressure is selected that does not exceed the threshold level, so that delivery occurs substantially only to the epithelial layer. Such site specific delivery of therapeutic agents permits localized delivery of substances (for example to the interstitial tissue of an organ) in concentrations that may otherwise produce systemic toxicity.Type: ApplicationFiled: January 17, 2008Publication date: October 30, 2008Inventors: Stephen M. Wiener, Robert F. Hoyt, John R. Deleonardis, Randall R. Clevenger, Robert J. Lutz, Douglas V. Christini, Brian Safer
-
Patent number: 6821511Abstract: A composition for delivering at least one DNA sequence encoding a desired protein or polypeptide (such as a therapeutic agent) to a cell. The composition comprises an adeno-associated virus rep protein (or a nucleic acid sequence encoding an adeno-associated virus rep protein) and a genetic construct including at least one DNA sequence encoding a protein or polypeptide or genetic transcript of interest and a promoter controlling the at least one DNA sequence. The genetic construct also includes a first adeno-associated virus ITR or protein or derivative thereof and a second adeno-associated virus ITR or a portion or derivative thereof. The first and second adeno-associated virus ITRs or portions or derivatives thereof flank the at least one DNA sequence encoding the protein or polypeptide or genetic transcript of interest and the promoter controlling the at least one DNA sequence encoding the protein or polypeptide or genetic transcript of interest.Type: GrantFiled: August 3, 2001Date of Patent: November 23, 2004Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Robert M. Kotin, Brian Safer, John A. Chiorini, Matthew D. Weitzman, Roland A. Owens, Stephen M. Wiener
-
Publication number: 20040086490Abstract: The present invention provides an adeno-associated virus 4 (AAV4) virus and vectors and particles derived therefrom. In addition, the present invention provides methods of delivering a nucleic acid to a cell using the AAV4 vectors and particles.Type: ApplicationFiled: November 20, 2003Publication date: May 6, 2004Applicant: Sumesh KaushalInventors: John A. Chiorini, Robert M. Kotin, Brian Safer
-
Publication number: 20030215422Abstract: The present invention provides an adeno-associated virus 4 (AAV4) virus and vectors and particles derived therefrom. In addition, the present invention provides methods of delivering a nucleic acid to a cell using the AAV4 vectors and particles.Type: ApplicationFiled: November 26, 1999Publication date: November 20, 2003Inventors: JOHN A. CHIORINI, ROBERT M. KOTIN, BRIAN SAFER
-
Publication number: 20020012997Abstract: A composition for delivering at least one DNA sequence encoding a desired protein or polypeptide (such as a therapeutic agent) to a cell. The composition comprises an adeno-associated virus rep protein (or a nucleic acid sequence encoding an adeno-associated virus rep protein) and a genetic construct including at least one DNA sequence encoding a protein or polypeptide or genetic transcript of interest and a promoter controlling the at least one DNA sequence. The genetic construct also includes a first adeno-associated virus ITR or protein or derivative thereof and a second adeno-associated virus ITR or a portion or derivative thereof. The first and second adeno-associated virus ITRs or portions or derivatives thereof flank the at least one DNA sequence encoding the protein or polypeptide or genetic transcript of interest and the promoter controlling the at least one DNA sequence encoding the protein or polypeptide or genetic transcript of interest.Type: ApplicationFiled: August 3, 2001Publication date: January 31, 2002Inventors: Robert M. Kotin, Brian Safer, John A. Chiorini, Matthew D. Weitzman, Roland A. Owens, Stephen M. Wiener
-
Patent number: 6342390Abstract: A composition for delivering at least one DNA sequence encoding a desired protein or polypeptide (such as a therapeutic agent) to a cell. The composition comprises an adeno-associated virus rep protein (or a nucleic acid sequence encoding an adeno-associated virus rep protein) and a genetic construct including at least one DNA sequence encoding a protein or polypeptide or genetic transcript of interest and a promoter controlling the at least one DNA sequence. The genetic construct also includes a first adeno-associated virus ITR or protein or derivative thereof and a second adeno-associated virus ITR or a portion or derivative thereof. The first and second adeno-associated virus ITRs or portions or derivatives thereof flank the at least one DNA sequence encoding the protein or polypeptide or genetic transcript of interest and the promoter controlling the at least one DNA sequence encoding the protein or polypeptide or genetic transcript of interest.Type: GrantFiled: November 23, 1994Date of Patent: January 29, 2002Assignee: The United States of America as represented by the Secretary of Health and Human ServicesInventors: Stephen M. Wiener, John A. Chiorini, Brian Safer, Robert M. Kotin, Matthew D. Weitzman, Roland A. Owens
-
Patent number: 5693531Abstract: A vector system comprising a first vector, which is an adeno-associated viral vector, and which includes an adeno-associated virus 5'ITR, an adeno-associated virus 3'ITR, and at least one heterologous DNA sequence. The vector system also includes a second vector which includes an inducible origin of replication, such as an SV40 origin of replication, which is capable of being induced or activated by an agent, such as the SV40 T-antigen. The second vector also includes DNA sequences encoding the adeno-associated virus rep and cap proteins. When induced by an agent, the second vector may replicate to a high copy number, and thereby increased numbers of infectious adeno-associated viral particles may be generated.Type: GrantFiled: November 24, 1993Date of Patent: December 2, 1997Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: John A. Chiorini, Robert Kotin, Brian Safer, Elena Urcelay